An ambient-temperature stable nanoparticle-based vaccine for nasal application that confers long-lasting immunogenicity to carried antigens
Frontiers in Immunology, ISSN: 1664-3224, Vol: 13, Page: 1057499
2022
- 4Citations
- 8Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations4
- Citation Indexes4
- Captures8
- Readers8
- Mentions1
- News Mentions1
- News1
Most Recent News
Reports Outline Vaccines Study Results from National Autonomous University of Mexico (UNAM) (An ambient-temperature stable nanoparticle-based vaccine for nasal application that confers long-lasting immunogenicity to carried antigens)
2022 NOV 11 (NewsRx) -- By a News Reporter-Staff News Editor at Proteomics Daily -- Current study results on vaccines have been published. According to
Article Description
Polyhedrins are viral proteins present in a large family of baculoviruses that form occlusion bodies (polyhedra). These structures protect the virus particles from the outside environment until they are ingested by susceptible insects. Occluded viruses can sustain inclement weather for long periods of time. Therefore, the polyhedra is a natural preservative that keeps the viral structure intact at ambient temperature for years. In a previous study we identified the first 110 amino acids from polyhedrin (PH) as a good candidate to carry antigens of interest. As a proof of concept, we produced a fusion protein with PH and the green fluorescent protein (PHGFP). The fusion protein associates spontaneously during its synthesis resulting in the formation of nanoparticles. Nasal immunization with these nanoparticles and in the absence of any adjuvant, results in a robust immune response with the production of IgG immunoglobulins that remained elevated for months and that selectively recognize the GFP but not PH. These results indicate that PH is poorly immunogenic but capable of enhancing the immune response to GFP.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85142040450&origin=inward; http://dx.doi.org/10.3389/fimmu.2022.1057499; http://www.ncbi.nlm.nih.gov/pubmed/36389760; https://www.frontiersin.org/articles/10.3389/fimmu.2022.1057499/full; https://dx.doi.org/10.3389/fimmu.2022.1057499; https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1057499/full
Frontiers Media SA
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know